OZ Minerals (ASX:OZL) sees no material impacts at mine sites
15 Apr 2020 - OZ Minerals (ASX:OZL) has reported that despite the recent COVID-19 crisis, the company has not experienced any material production impacts at its mine sites this year
15 Apr 2020 - OZ Minerals (ASX:OZL) has reported that despite the recent COVID-19 crisis, the company has not experienced any material production impacts at its mine sites this year
15 Apr 2020 - The Orocobre (ASX:ORE) acquisition of Canadian lithium developer Advantage Lithium is set to be completed after the company was given approval for the takeover by Advantage shareholders.
15 Apr 2020 - Baby formula brand Bubs Australia (ASX:BUB) have reported a positive operating cashflow of $2.3 million on sales of $23.4 million for the first 2020 quarter ending March 31, 2020.
15 Apr 2020 - Production at Lynas Corporation's (ASX:LYC) Malaysian plant is set to continue it’s temporary halt.
14 Apr 2020 - Genetic Signatures (ASX:GSS) has received notice from the Therapeutic Goods Administration (“TGA”) that its EasyScreenTM SARS-CoV-2 Detection Kit has been approved to be listed on the ARTG in Australia.
14 Apr 2020 - Smart building materials company ClearVue Technologies (ASX:CPV) has entered into a Collaboration Agreement with eLstar Dynamics B.V in the Netherlands.
14 Apr 2020 - InvoCare (AX:IVC) funeral homes is raising $150m through an underwritten institutional Placement to continue momentum achieved on its growth initiatives through the temporary restrictions on the funeral industry as a result of COVID-19.
14 Apr 2020 - Cyclopharm (ASX:CYC) is pleased to announce that the United States Food and Drug Administration (USFDA) has granted the Company a full application fee waiver of USD $2.9 million related to its recently submitted New Drug Application (NDA) for Technegas.
14 Apr 2020 - Smart building materials company ClearVue Technologies (ASX:CPV) has entered into a Collaboration Agreement with eLstar Dynamics B.V in the Netherlands.
14 Apr 2020 - Cyclopharm (ASX:CYC) is pleased to announce that the United States Food and Drug Administration (USFDA) has granted the Company a full application fee waiver of USD $2.9 million related to its recently submitted New Drug Application (NDA) for Technegas.